Table 2.
Apyrase treatment alters relative PBMC number
| Treatment | Unstimulated (48 h) | PHA (48 h) | CD3/28 (48 Hours) |
| Negative | 1 ± 0 | 3.046 ± 0.158 | 5.517 ± 2.372 |
| Negative + Apyrase | 1 ± 0 | 1.832 ± 0.500 | 2.141 ± 0.678 |
| AR-C | 1.377 ± 0.124 | 2.863 ± 0.283 | 5.161 ± 1.599 |
| AR-C+ Apyrase | 0.962 ± 0.063 | 1.473 ± 0.339 | 1.856 ± 0.559 |
| 2MeSADP | 1.45 ± 0.136 | 3.802 ± 0.266 | 5.038 ± 1.284 |
| 2MeSADP + Apyrase | 0.948 ± 0.053 | 1.535 ± 0.360 | 1.989 ± 0.617 |
| 2MeSADP + ARC | 1.058 ± 0.102 | 3.052 ± 0.307 | 6.291 ± 1.824 |
| 2MeSADP + ARC + Apyrase | 0.963 ± 0.052 | 1.781 ± 0.547 | 2.383 ± 0.877 |
| Treatment | Unstimulated (72 h) | PHA (72 h) | CD3/28 (72 Hours) |
| Negative | 1 ± 0 | 2.399 ± 0.171 | 3.858 ± 0.467 |
| Negative + Apyrase | 1 ± 0 | 1.042 ± 0.085 | 0.827 ± 0.135 |
| AR-C | 0.977 ± 0.032 | 2.467 ± 0.419 | 3.869 ± 0.226 |
| AR-C+ Apyrase | 0.909 ± 0.025 | 0.864 ± 0.047 | 0.705 ± 0.078 |
| 2MeSADP | 1.083 ± 0.032 | 3.070 ± 0.253 | 2.957 ± 0.234 |
| 2MeSADP + Apyrase | 1.170 ± 0.151 | 0.890 ± 0.072 | 0.691 ± 0.059 |
| 2MeSADP + ARC | 0.886 ± 0.045 | 1.935 ± 0.330 | 3.826 ± 0.380 |
| 2MeSADP + ARC + Apyrase | 1.027 ± 0.011 | 0.995 ± 0.151 | 0.853 ± 0.166 |
PBMC were stimulated with anti-CD3/CD28 or PHA or without stimuli (unstimulated) for 48 or 72 h. Cells were pre-treated with 2MeSADP (100 nM), AR-C (100 nM) or 2MeSADP /AR-C (both 100 nM). Negative control did not receive any treatment. When appropriate cells were pre-treated with Apyrase (0.2 units/ml) (patter bars). Cell activity was analyzed using a WST-1 cell proliferation assay kit for unstimulated, CD3/CD28 or PHA stimulated cells. Data of the samples untreated or treated with apyrase are expressed as relative absorbance compared with unstimulated untreated cells and unstimulated untreated cells + apyrase respectively. Means ± S.E.M. are plotted (*p < 0.05, n = 5)